Aikido pharma announces share repurchase program

New york , jan. 24, 2022 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki ) ("aikido" or the "company"), a clinical and early-stage drug development company, today announced that its board of directors (the "board") has authorized a share repurchase program to repurchase up to $3 million of the company's outstanding common stock. the share repurchase authorization is effective immediately.
DOMH Ratings Summary
DOMH Quant Ranking